ArticleProbiotics and antimicrobial proteins2026
RK-14: A Novel Antimicrobial Peptide Targeting Multidrug-Resistant Bacteria and Catheter-Associated Biofilms.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antimicrobial resistance (AMR) and biofilm-associated infections caused by multidrug-resistant (MDR) bacteria pose major challenges to effective antimicrobial therapy. In this study, the short cationic antimicrobial peptide RK-14 (RIWKIWKKIWKIWK-NH₂) was designed using an integrated artificial intelligence (AI)- and machine learning (ML)-assisted approach and subsequently evaluated using computational predictions and in vitro analyses. RK-14 exhibited bactericidal activity against methicillin-resistant Staphylococcus aureus and ESBL-positive Escherichia coli, with MICs of 16-64 µM and MBCs of 32-128 µM. RK-14 showed strong concentration-dependent antibiofilm activity (80-99% inhibition), outperforming LL-37, vancomycin, and colistin. Against mature catheter-associated biofilms, RK-14 achieved 87-91% eradication at 1 × MIC, compared with 77-87% for LL-37 and markedly lower activity of vancomycin and colistin. Consistently, catheter-associated CFU counts were significantly reduced following RK-14 treatment compared with the comparator treatments. Fluorescence microscopy revealed pronounced reductions in bacterial numbers and marked morphological alterations in both E. coli and S. aureus. Membrane disruption was further supported by strong membrane-binding affinity and increased propidium iodide uptake. RK-14 also suppressed key biofilm- and virulence-associated genes, including luxS, csgD, icaD, and spa. In ESBL-positive E. coli, RK-14 reduced luxS and csgD expression to approximately 0.36-0.48-fold and 0.17-0.43-fold, respectively, relative to the untreated control. In methicillin-resistant S. aureus, RK-14 reduced icaD and spa expression to approximately 0.47-fold and 0.64-fold, respectively. These effects were generally greater than or comparable to those observed following LL-37 and conventional antibiotic treatment. The peptide retained activity under various temperature and ionic conditions and showed low cytotoxicity at effective concentrations, although hemolysis increased at higher concentrations. Overall, RK-14 demonstrates potent bactericidal and antibiofilm activity, effective disruption of mature catheter-associated biofilms, and a favorable preliminary selectivity profile, supporting its further investigation as a promising lead peptide against MDR bacterial infections.
Indexed as
Identifiers
42809173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.